TY - JOUR
T1 - Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states
T2 - a next generation sequencing study of 183 patients
AU - Dasari, Surendra
AU - McCarthy, Michael R.
AU - Wojcik, Antonina A.
AU - Pitel, Beth A.
AU - Samaddar, Arpan
AU - Tekin, Burak
AU - Whaley, Rumeal D.
AU - Raghunathan, Aditya
AU - Hernandez, Loren Herrera
AU - Jimenez, Rafael E.
AU - Stish, Brad J.
AU - Thompson, R. Houston
AU - Leibovich, Bradley C.
AU - Boorjian, Stephen A.
AU - Jeffrey Karnes, R.
AU - Childs, Daniel S.
AU - Quevedo, J. Fernando
AU - Kwon, Eugene D.
AU - Pagliaro, Lance C.
AU - Costello, Brian A.
AU - Halling, Kevin C.
AU - Cheville, John C.
AU - Kipp, Benjamin R.
AU - Gupta, Sounak
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Limited 2024.
PY - 2025/6
Y1 - 2025/6
N2 - Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.
AB - Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.
UR - https://www.scopus.com/pages/publications/85186178739
UR - https://www.scopus.com/pages/publications/85186178739#tab=citedBy
U2 - 10.1038/s41391-024-00814-2
DO - 10.1038/s41391-024-00814-2
M3 - Article
C2 - 38413763
AN - SCOPUS:85186178739
SN - 1365-7852
VL - 28
SP - 506
EP - 508
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 2
ER -